Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

2.425 +0.035 (+1.46%)
Streaming Delayed Price Updated: 10:15 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Ovid Therapeutics to Participate in Upcoming Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
OVID Therapeutics Inc (NASDAQ:OVID) Passes Minervini's High-Growth Momentum and Trend Template Filters ↗
Via Chartmill
News headline image
Here's Why Ovid Therapeutics Stock Popped Higher Today ↗
Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2. 
Via The Motley Fool
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Participate in Upcoming Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
OVID THERAPEUTICS INC (NASDAQ:OVID) Announces Leadership Transition and Key Pipeline Milestones Following Q3 2025 Results ↗
Ovid Therapeutics announces CEO succession plan and key pipeline progress for epilepsy drug OV329 and KCC2 activators, backed by a strong cash position. 
Via Chartmill
News headline image
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why ↗
The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures. 
Via Stocktwits
Topics Intellectual Property
News headline image
These stocks that are showing activity before the opening bell on Friday. ↗
Wondering what's happening in Friday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued... 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.